Abstract
Despite being collectively among the most frequent congenital developmental conditions worldwide, differences of sex development (DSD) lack recognition and research funding. As a result, what constitutes optimal management remains uncertain. Identification of the individual conditions under the DSD umbrella is challenging and molecular genetic diagnosis is frequently not achieved, which has psychosocial and health-related repercussions for patients and their families. New genomic approaches have the potential to resolve this impasse through better detection of protein-coding variants and ascertainment of under-recognized aetiology, such as mosaic, structural, non-coding or epigenetic variants. Ultimately, it is hoped that better outcomes data, improved understanding of the molecular causes and greater public awareness will bring an end to the stigma often associated with DSD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lee, P. A. et al. Consensus statement on management of intersex disorders. Pediatrics 118, e488–e500 (2006). This seminal publication of the 2005 International Consensus Conference on Management of Intersex Disorders, convened by the Lawson Wilkins Pediatric Endocrine Society (LWPES) and the European Society for Paediatric Endocrinology (ESPE), coined the term DSD and laid out the current framework for nomenclature, diagnosis and interdisciplinary management of DSD.
Parivesh, A., Barseghyan, H., Délot, E. & Vilain, E. Translating genomics to the clinical diagnosis of disorders/differences of sex development. Curr. Top. Dev. Biol. 134, 317–375 (2019). This review of the genetic aetiology and testing of DSD provides a comprehensive analysis of the available evidence of pathogenicity, and the current limitations of the ClinVar database, for 69 DSD genes.
Délot, E. C. & Vilain, E. in Yen & Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management 8th edn (Strauss, J. F. III & Barbieri, R. L.) 365–393 (Elsevier, 2018). This textbook chapter details clinical DSD categories, aetiology, testing and management approaches.
Hutson, J. M. & Kearsey, I. Disorders of sex development (DSD): not only babies with ambiguous genitalia. A practical guide for surgeons. Pediatr. Surg. Int. 33, 355–361 (2017).
Délot, E. C. et al. Genetics of disorders of sex development: the DSD-TRN experience. Endocrinol. Metab. Clin. North. Am. 46, 519–537 (2017). This publication lays out the principles of the practice standardization effort undertaken by the DSD-TRN and includes a report of early genetics data from its registry.
Ahmed, S. F., Bryce, J. & Hiort, O. International networks for supporting research and clinical care in the field of disorders of sex development. Endocr. Dev. 27, 284–292 (2014).
Lee, P. A. et al. Global disorders of sex development update since 2006: perceptions, approach and care. Horm. Res. Paediatr. 85, 158–180 (2016).
Sandberg, D. E., Gardner, M., Callens, N. & Mazur, T. Interdisciplinary care in disorders/differences of sex development (DSD): the psychosocial component of the DSD-Translational Research Network. Am. J. Med. Genet. C. Semin. Med. Genet. 175, 279–292 (2017).
Gomes, N. L., Chetty, T., Jorgensen, A. & Mitchell, R. T. Disorders of sex development-novel regulators, impacts on fertility, and options for fertility preservation. Int. J. Mol. Sci. 21, 2282 (2020).
Johnson, E. K. et al. Gonadal tissue cryopreservation for children with differences of sex development. Horm. Res. Paediatr. 92, 84–91 (2019).
Looijenga, L. H. J., Kao, C. S. & Idrees, M. T. Predicting gonadal germ cell cancer in people with disorders of sex development; insights from developmental biology. Int. J. Mol. Sci. 20, 5017 (2019).
Morin, J. et al. Oncologic outcomes of pre-malignant and invasive germ cell tumors in patients with differences in sex development — a systematic review. J. Pediatr. Urol. 16, 576–582 (2020).
Adam, M. P. & Vilain, E. Emerging issues in disorders/differences of sex development (DSD). Am. J. Med. Genet. C. Semin. Med. Genet. 175, 249–252 (2017).
Gainotti, S. et al. Meeting patients’ right to the correct diagnosis: ongoing international initiatives on undiagnosed rare diseases and ethical and social issues. Int. J. Environ. Res. Public Health 15, 2072 (2018).
Austin, C. P. et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin. Transl. Sci. 11, 21–27 (2018).
Croft, B., Ayers, K., Sinclair, A. & Ohnesorg, T. Review disorders of sex development: the evolving role of genomics in diagnosis and gene discovery. Birth Defects Res. C. Embryo Today Rev. 108, 337–350 (2016).
Ahmed, F. et al. Disorders of sex development: advances in genetic diagnosis and challenges in management. Adv. Genomics Genet. 2015, 165–177 (2015).
Ohnesorg, T., Vilain, E. & Sinclair, A. H. The genetics of disorders of sex development in humans. Sex. Dev. 8, 262–272 (2014).
Ono, M. & Harley, V. R. Disorders of sex development: new genes, new concepts. Nat. Rev. Endocrinol. 9, 79–91 (2013).
Koopman, P., Sinclair, A. & Lovell-Badge, R. Of sex and determination: marking 25 years of Randy, the sex-reversed mouse. Development 143, 1633–1637 (2016). This article provides a lively account of the characterization of SRY as the key mammalian gonadal sex determination gene, told by three of the main protagonists.
Baxter, R. M. et al. Exome sequencing for the diagnosis of 46,XY disorders of sex development. J. Clin. Endocrinol. Metab. 100, E333–E344 (2015). This article reports an early use of clinical exome sequencing for DSD diagnosis on a cohort of 46,XY individuals with various DSD conditions.
Eggers, S. et al. Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort. Genome Biol. 17, 243 (2016).
Heeley, J. M. et al. Risk association of congenital anomalies in patients with ambiguous genitalia: a 22-year single-center experience. J. Pediatr. Urol. 14, 153.e1–153.e7 (2018).
Koopman, P. The curious world of gonadal development in mammals. Curr. Top. Dev. Biol. 116, 537–545 (2016).
León, N. Y., Reyes, A. P. & Harley, V. R. A clinical algorithm to diagnose differences of sex development. Lancet Diabetes Endocrinol. 7, 560–574 (2019). This article describes a recent comprehensive clinical algorithm that guides diagnosis and management of newborns with ambiguous genitalia.
Audi, L. et al. Genetics in endocrinology: approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 ‘DSDnet’. Eur. J. Endocrinol. 179, R197–R206 (2018).
Délot, E. C. & Vilain, E. J. Nonsyndromic 46,XX testicular disorders of sex development. GeneReviews [online], https://www.ncbi.nlm.nih.gov/books/NBK1416/ (updated 7 May 2015).
Mohnach, L., Fechner, P. Y. & Keegan, C. E. Nonsyndromic disorders of testicular development. GeneReviews [online], https://pubmed.ncbi.nlm.nih.gov/20301714/ (updated 2 Jun 2016).
Alhomaidah, D., McGowan, R. & Ahmed, S. F. The current state of diagnostic genetics for conditions affecting sex development. Clin. Genet. 91, 157–162 (2017).
Cools, M. et al. Caring for individuals with a difference of sex development (DSD): a consensus statement. Nat. Rev. Endocrinol. 14, 415–429 (2018). This consensus statement by European workgroups details approaches and data collection processes for management of individuals with DSD throughout their lifespan.
Speiser, P. W. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 4043–4088 (2018).
Speiser, P. W. et al. Newborn screening protocols and positive predictive value for congenital adrenal hyperplasia vary across the United States. Int. J. Neonatal Screen. 6, 37 (2020).
Krone, N. et al. Genotype–phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital adrenal Hhyperplasia Adult Study Executive (CaHASE) cohort. J. Clin. Endocrinol. Metab. 98, E346–E354 (2013).
Smet, M. E., Scott, F. P. & McLennan, A. C. Discordant fetal sex on NIPT and ultrasound. Prenat. Diagn. 40, 1353–1365 (2020).
Byers, H. M. et al. Discordant sex between fetal screening and postnatal phenotype requires evaluation. J. Perinatol. 39, 28–33 (2019).
Dhamankar, R., DiNonno, W., Martin, K. A., Demko, Z. P. & Gomez-Lobo, V. Fetal sex results of noninvasive prenatal testing and differences with ultrasonography. Obstet. Gynecol. 135, 1198–1206 (2020).
Dey, M., Sharma, S. & Aggarwal, S. Prenatal screening methods for aneuploidies. N. Am. J. Med. Sci. 5, 182–190 (2013).
Deng, C. et al. Clinical application of noninvasive prenatal screening for sex chromosome aneuploidies in 50,301 pregnancies: initial experience in a Chinese hospital. Sci. Rep. 9, 7767 (2019).
Neufeld-Kaiser, W. A., Cheng, E. Y. & Liu, Y. J. Positive predictive value of non-invasive prenatal screening for fetal chromosome disorders using cell-free DNA in maternal serum: independent clinical experience of a tertiary referral center. BMC Med. 13, 129 (2015).
Wang, Y. et al. Cell-free DNA screening for sex chromosome aneuploidies by non-invasive prenatal testing in maternal plasma. Mol. Cytogenet. 13, 10 (2020).
Croft, B., Ohnesorg, T. & Sinclair, A. H. The role of copy number variants in disorders of sex development. Sex. Dev. 12, 19–29 (2018). This article provides a comprehensive literature review of the impact of structural variants in DSD aetiology.
Ledig, S. et al. Array-CGH analysis in patients with syndromic and non-syndromic XY gonadal dysgenesis: evaluation of array CGH as diagnostic tool and search for new candidate loci. Hum. Reprod. 25, 2637–2646 (2010).
Tannour-Louet, M. et al. Identification of de novo copy number variants associated with human disorders of sexual development. PLoS ONE 5, e15392 (2010).
Harrison, S. M., Seideman, C. & Baker, L. A. DNA copy number variations in patients with persistent cloaca. J. Urol. 191, 1543–1546 (2014).
Backhouse, B. et al. Identification of candidate genes for Mayer–Rokitansky–Küster–Hauser syndrome using genomic approaches. Sex. Dev. 13, 26–34 (2019).
Takahashi, K. et al. Exome and copy number variation analyses of Mayer–Rokitansky–Küster–Hauser syndrome. Hum. Genome Var. 5, 27 (2018).
Amarillo, I. E. et al. Integrated small copy number variations and epigenome maps of disorders of sex development. Hum. Genome Var. 3, 16012 (2016).
New, M. I. et al. Genotype–phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc. Natl Acad. Sci. USA 110, 2611–2616 (2013).
Narasimhan, M. L. & Khattab, A. Genetics of congenital adrenal hyperplasia and genotype–phenotype correlation. Fertil. Steril. 111, 24–29 (2019).
Koboldt, D. C. Best practices for variant calling in clinical sequencing. Genome Med. 12, 91 (2020).
Arboleda, V. A. et al. Targeted massively parallel sequencing provides comprehensive genetic diagnosis for patients with disorders of sex development. Clin. Genet. 83, 35–43 (2013).
Kim, J. H. et al. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development. Mol. Cell. Endocrinol. 444, 19–25 (2017).
Özen, S. et al. Rapid molecular genetic diagnosis with next-generation sequencing in 46,XY disorders of sex development cases: efficiency and cost assessment. Horm. Res. Paediatr. 87, 81–87 (2017).
Fan, Y. et al. Diagnostic application of targeted next-generation sequencing of 80 genes associated with disorders of sexual development. Sci. Rep. 7, 44536 (2017).
Barseghyan, H., Delot, E. C. & Vilain, E. New technologies to uncover the molecular basis of disorders of sex development. Mol. Cell. Endocrinol. 468, 60–69 (2018).
Hughes, L. A. et al. Next generation sequencing (NGS) to improve the diagnosis and management of patients with disorders of sex development (DSD). Endocr. Connect. 8, 100–110 (2019).
Buonocore, F. & Achermann, J. C. Primary adrenal insufficiency: new genetic causes and their long-term consequences. Clin. Endocrinol. 92, 11–20 (2020).
Barseghyan, H., Delot, E. & Vilain, E. New genomic technologies: an aid for diagnosis of disorders of sex development. Horm. Metab. Res. 47, 312–320 (2015).
Stavropoulos, D. J. et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genom. Med. 1, 15012 (2016).
Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: diagnosing rare disease in children. Nat. Rev. Genet. 19, 253–268 (2018).
Belkadi, A. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc. Natl Acad. Sci. USA 112, 5473–5478 (2015).
Barbitoff, Y. A. et al. Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage. Sci. Rep. 10, 2057 (2020).
Ravishankar, A., Derraik, J. G. B., Mathai, S., Cutfield, W. S. & Hofman, P. L. Karyotypes, confined blood chimerism, and confusion: a case of genetic sex mislabelling and its potential consequences. N. Z. Med. J. 128, 62–65 (2015).
Strain, L., Dean, J. C. S., Hamilton, M. P. R. & Bonthron, D. T. A true hermaphrodite chimera resulting from embryo amalgamation after in vitro fertilization. N. Engl. J. Med. 338, 166–169 (1998).
Hatano, M., Fukuzawa, R. & Hasegawa, Y. The mosaicism ratio of 45,X may explain the phenotype in a case of mixed gonadal dysgenesis. Sex. Dev. 12, 175–179 (2018).
Boucekkine, C. et al. The sole presence of the testis-determining region of the Y chromosome (SRY) in 46,XX patients is associated with phenotypic variability. Horm. Res. Paediatr. 37, 236–240 (1992).
Isidor, B. et al. Familial frameshift SRY mutation inherited from a mosaic father with testicular dysgenesis syndrome. J. Clin. Endocrinol. Metab. 94, 3467–3471 (2009).
Murdock, D. R. et al. Whole-exome sequencing for diagnosis of Turner syndrome: toward next-generation sequencing and newborn screening. J. Clin. Endocrinol. Metab. 102, 1529–1537 (2017).
Hu, P. et al. Low-level parental mosaicism affects the recurrence risk of holoprosencephaly. Genet. Med. 21, 1015–1020 (2019).
Camats, N., Fernández-Cancio, M., Audí, L., Schaller, A. & Flück, C. E. Broad phenotypes in heterozygous NR5A1 46,XY patients with a disorder of sex development: an oligogenic origin? Eur. J. Hum. Genet. 26, 1329–1338 (2018).
Werner, R. et al. New NR5A1 mutations and phenotypic variations of gonadal dysgenesis. PLoS ONE 12, e0176720 (2017).
Flück, C. E. et al. Broad phenotypes of disorders/differences of sex development in MAMLD1 patients through oligogenic disease. Front. Genet. 10, 746 (2019).
Lindstrand, A. et al. Copy-number variation contributes to the mutational load of Bardet–Biedl syndrome. Am. J. Hum. Genet. 99, 318–336 (2016).
Baetens, D. et al. NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development. Genet. Med. 19, 367–376 (2017).
Chaisson, M. J. P. et al. Multi-platform discovery of haplotype-resolved structural variation in human genomes. Nat. Commun. 10, 1784 (2019). This landmark benchmarking study compares the respective outputs of LRS, SRS and OGM data sets for detection of structural variants of various sizes and types on the same genome.
Ho, S. S., Urban, A. E. & Mills, R. E. Structural variation in the sequencing era. Nat. Rev. Genet. 21, 171–189 (2020).
Sedlazeck, F. J., Lee, H., Darby, C. A. & Schatz, M. C. Piercing the dark matter: bioinformatics of long-range sequencing and mapping. Nat. Rev. Genet. 19, 329–346 (2018).
Chan, S. et al. Structural variation detection and analysis using bionano optical mapping. Methods Mol. Biol. 1833, 193–203 (2018).
Mak, A. C. Y. et al. Genome-wide structural variation detection by genome mapping on nanochannel arrays. Genetics 202, 351–362 (2016).
Levy-Sakin, M. et al. Genome maps across 26 human populations reveal population-specific patterns of structural variation. Nat. Commun. 10, 1025 (2019).
Bocklandt, S., Hastie, A. & Cao, H. Bionano genome mapping: high-throughput, ultra-long molecule genome analysis system for precision genome assembly and haploid-resolved structural variation discovery. Adv. Exp. Med. Biol. 1129, 97–118 (2019).
Jaratlerdsiri, W. et al. Next generation mapping reveals novel large genomic rearrangements in prostate cancer. Oncotarget 8, 23588–23602 (2017).
Du, C. et al. A tandem duplication of BRCA1 exons 1–19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome. Breast Cancer Res. Treat. 172, 561–569 (2018).
Dixon, J. R. et al. Integrative detection and analysis of structural variation in cancer genomes. Nat. Genet. 50, 1388–1398 (2018).
Barseghyan, H. et al. Next-generation mapping: a novel approach for detection of pathogenic structural variants with a potential utility in clinical diagnosis. Genome Med. 9, 1–11 (2017). This paper explains the OGM technology and demonstrates its clinical utility for clinical diagnosis in human disease on a cohort of individuals with Duchenne muscular dystrophy.
Sharim, H. et al. Long-read single-molecule maps of the functional methylome. Genome Res. 29, 646–656 (2019).
Rieken, A., Bossler, A. D., Mathews, K. D. & Moore, S. A. CLIA laboratory testing for facioscapulohumeral dystrophy (FSHD): a retrospective analysis. Neurology 96, e1054–e1062 (2021).
Bhattacharya, S., Barseghyan, H., Délot, E. C. & Vilain, E. nanotatoR: a tool for enhanced annotation of genomic structural variants. BMC Genomics 22, 10 (2021).
Mantere, T., Kersten, S. & Hoischen, A. Long-read sequencing emerging in medical genetics. Front. Genet. 10, 426 (2019).
Amarasinghe, S. L. et al. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 21, 30 (2020).
Mahmoud, M. et al. Structural variant calling: the long and the short of it. Genome Biol. 20, 246 (2019).
Miga, K. H. et al. Telomere-to-telomere assembly of a complete human X chromosome. Nature 585, 79–84 (2020).
Arboleda, V. A. et al. Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat. Genet. 44, 788–792 (2012).
García-Acero, M., Moreno, O., Suárez, F. & Rojas, A. Disorders of sexual development: current status and progress in the diagnostic approach. Curr. Urol. 13, 169–178 (2020).
Gimelli, G., Giorda, R., Beri, S., Ginielli, S. & Zuffardi, O. A 46,X,inv(Y) young woman with gonadal dysgenesis and gonadoblastoma: cytogenetics, molecular, and methylation studies. Am. J. Med. Genet. 140 A, 40–45 (2006).
Aref-Eshghi, E. et al. Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions. Am. J. Hum. Genet. 104, 685–700 (2019).
Liu, Q. et al. Detection of DNA base modifications by deep recurrent neural network on Oxford Nanopore sequencing data. Nat. Commun. 10, 2449 (2019).
Yang, Y. & Scott, S. A. in Methods in Molecular Biology Vol. 1654 (eds Kaufmann, M., Klinger, C. & Savelsbergh, A.) 125–134 (Springer, 2017).
Beaulaurier, J. et al. Single molecule-level detection and long read-based phasing of epigenetic variations in bacterial methylomes. Nat. Commun. 6, 7438 (2015).
Gouil, Q. & Keniry, A. Latest techniques to study DNA methylation. Essays Biochem. 63, 639–648 (2019).
Liu, Y. et al. Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS. Genome Biol. 21, 54 (2020).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015). This joint report from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) established the criteria and guidelines currently used by all accredited clinical sequencing facilities and research laboratories to interpret and classify sequence variants (often called the ACMG criteria).
Gelman, H. et al. Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation. Genome Med. 11, 85 (2019).
Kopanos, C. et al. VarSome: the human genomic variant search engine. Bioinformatics 35, 1978–1980 (2018).
Nykamp, K. et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria. Genet. Med. 19, 1105–1117 (2017).
Gulía, C. et al. in European Review for Medical and Pharmacological Sciences Vol. 22 (eds Adam, M. P. et al.) 3873–3887 (Univ. of Washington, Seattle, 2018).
Imbeaud, S. et al. Molecular genetics of the persistent Müllerian duct syndrome: a study of 19 families. Hum. Mol. Genet. 3, 125–131 (1994).
Imbeaud, S. et al. A 27 base-pair deletion of the anti-Mullerian type II receptor gene is the most common cause of the persistent Mullerian duct syndrome. Hum. Mol. Genet. 5, 1269–1277 (1996).
GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
Baetens, D., Mendonça, B. B., Verdin, H., Cools, M. & De Baere, E. Non-coding variation in disorders of sex development. Clin. Genet. 91, 163–172 (2017).
Croft, B. et al. Human sex reversal is caused by duplication or deletion of core enhancers upstream of SOX9. Nat. Commun. 9, 5319 (2018).
Hornig, N. C. et al. A recurrent germline mutation in the 5′UTR of the androgen receptor causes complete androgen insensitivity by activating aberrant uORF translation. PLoS ONE 11, e0154158 (2016).
Smedley, D. et al. A whole-genome analysis framework for effective identification of pathogenic regulatory variants in Mendelian disease. Am. J. Hum. Genet. 99, 595–606 (2016).
Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–D868 (2016).
Caron, B., Luo, Y. & Rausell, A. NCBoost classifies pathogenic non-coding variants in Mendelian diseases through supervised learning on purifying selection signals in humans. Genome Biol. 20, 32 (2019).
Kwasnieski, J. C., Fiore, C., Chaudhari, H. G. & Cohen, B. A. High-throughput functional testing of ENCODE segmentation predictions. Genome Res. 24, 1595–1602 (2014).
ENCODE Project Consortium. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
Pranzatelli, T. J. F., Michael, D. G. & Chiorini, J. A. ATAC2GRN: optimized ATAC-seq and DNase1-seq pipelines for rapid and accurate genome regulatory network inference. BMC Genomics 19, 563 (2018).
Shen, S. Q. et al. Massively parallel cis-regulatory analysis in the mammalian central nervous system. Genome Res. 26, 238–255 (2016).
Sharpe, R. M., McKinnell, C., Kivlin, C. & Fisher, J. S. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. Reproduction 125, 769–784 (2003).
Bernard, P., Sim, H., Knower, K., Vilain, E. & Harley, V. Human SRY inhibits β-catenin-mediated transcription. Int. J. Biochem. Cell Biol. 40, 2889–2900 (2008).
Bernard, P. et al. Wnt signaling in ovarian development inhibits Sf1 activation of Sox9 via the Tesco enhancer. Endocrinology 153, 901–912 (2012).
Alankarage, D. et al. SOX9 regulates expression of the male fertility gene Ets variant factor 5 (ETV5) during mammalian sex development. Int. J. Biochem. Cell Biol. 79, 41–51 (2016).
Lee, J. et al. Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson’s disease. Proc. Natl Acad. Sci. USA 116, 16577–16582 (2019).
Knower, K. C. et al. Failure of SOX9 regulation in 46XY disorders of sex development with SRY, SOX9 and SF1 mutations. PLoS ONE 6, e17751 (2011).
Matson, C. K. et al. DMRT1 prevents female reprogramming in the postnatal mammalian testis. Nature 476, 101–105 (2011).
Uhlenhaut, N. H. et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 139, 1130–1142 (2009).
Rahmoun, M. et al. In mammalian foetal testes, SOX9 regulates expression of its target genes by binding to genomic regions with conserved signatures. Nucleic Acids Res. 45, 7191–7211 (2017).
Liang, J. et al. Induction of Sertoli-like cells from human fibroblasts by NR5A1 and GATA4. eLife 8, e48767 (2019).
Rodríguez Gutiérrez, D., Eid, W. & Biason-Lauber, A. A human gonadal cell model from induced pluripotent stem cells. Front. Genet. 9, 1–14 (2018).
Hannema, S. E. & De Rijke, Y. B. Improving laboratory assessment in disorders of sex development through a multidisciplinary network. Sex. Dev. 12, 135–139 (2018).
Kulle, A. et al. Steroid hormone analysis in diagnosis and treatment of DSD: position paper of EU COST Action BM 1303 ‘DSDnet’. Eur. J. Endocrinol. 176, P1–P9 (2017). This position paper reports the recommendations developed by the European Cooperation in Science and Technology (EU-COST) workgroup, DSDnet, for harmonization of steroid hormone analysis in diagnosis and treatment of DSD.
Rolston, A. M. et al. Disorders of sex development (DSD): clinical service delivery in the United States. Am. J. Med. Genet. C. Semin. Med. Genet. 175, 268–278 (2017).
Kyriakou, A. et al. Current models of care for disorders of sex development — results from an International survey of specialist centres. Orphanet J. Rare Dis. 11, 155 (2016).
Vora, K. A. & Srinivasan, S. A guide to differences/disorders of sex development/intersex in children and adolescents. Aust. J. Gen. Pract. 49, 417–422 (2020).
Farnaes, L. et al. Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom. Med. 3, 10 (2018).
Meng, L. et al. Use of exome sequencing for infants in intensive care units ascertainment of severe single-gene disorders and effect on medical management. JAMA Pediatr. 171, e173438–e173438 (2017).
Smith, L. D., Willig, L. K. & Kingsmore, S. F. Whole-exome sequencing and whole-genome sequencing in critically ill neonates suspected to have single-gene disorders. Cold Spring Harb. Perspect. Med. 6, a023168 (2016).
Chung, C. C. Y. et al. Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Reg. Health West. Pac. 1, 100001 (2020).
Mestek-Boukhibar, L. et al. Rapid paediatric sequencing (RaPS): comprehensive real-life workflow for rapid diagnosis of critically ill children. J. Med. Genet. 55, 721–728 (2018).
Lunke, S. et al. Feasibility of ultra-rapid exome sequencing in critically ill infants and children with suspected monogenic conditions in the Australian public health care system. J. Am. Med. Assoc. 323, 2503–2511 (2020).
Balogh, E. P., Miller, B. T., Ball, J. R. & National Academies of Sciences Medicine and Engineering. in Improving Diagnosis in Health Care (eds Balogh, E. P., Miller, B. T. & Ball, J. R.) (National Academies Press, 2015).
Sultan, C. et al. Disorders of androgen action. Semin. Reprod. Med. 20, 217–228 (2002).
Lek, N. et al. Low frequency of androgen receptor gene mutations in 46 XY DSD, and fetal growth restriction. Arch. Dis. Child. 99, 358–361 (2014).
Eozenou, C. et al. Testis formation in XX individuals resulting from novel pathogenic variants in Wilms’ tumor 1 (WT1) gene. Proc. Natl Acad. Sci. USA 117, 13680–13688 (2020).
Hutson, J. M., Grover, S. R., O’Connell, M. & Pennell, S. D. Malformation syndromes associated with disorders of sex development. Nat. Rev. Endocrinol. 10, 476–487 (2014).
Cox, K. et al. Novel associations in disorders of sex development: findings from the I-DSD registry. J. Clin. Endocrinol. Metab. 99, E348–E355 (2014).
Ferraz-de-Souza, B., Lin, L. & Achermann, J. C. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol. Cell. Endocrinol. 336, 198–205 (2011).
Philibert, P. et al. Predominant Sertoli cell deficiency in a 46,XY disorders of sex development patient with a new NR5A1/SF-1 mutation transmitted by his unaffected father. Fertil. Steril. 95, 1788.e5–1788.e9 (2011).
Flück, C. et al. Standardised data collection for clinical follow-up and assessment of outcomes in differences of sex development (DSD): recommendations from the COST action DSDnet. Eur. J. Endocrinol. 181, 545–564 (2019).
Röhle, R. et al. Participation of adults with disorders/differences of sex development (DSD) in the clinical study dsd-LIFE: design, methodology, recruitment, data quality and study population. BMC Endocr. Disord. 17, 52 (2017).
Fausto-Sterling, A. Sexing the Body: Gender Politics and the Construction of Sexuality (Basic Books, 2000).
Pohl, H. G., Joyce, G. F., Wise, M. & Cilento, B. G. Cryptorchidism and hypospadias. J. Urol. 177, 1646–1651 (2007).
Kelly, J. Environmental scan of cystic fibrosis research worldwide. J. Cyst. Fibros. 16, 367–370 (2017).
Biason-Lauber, A., Konrad, D., Meyer, M., DeBeaufort, C. & Schoenle, E. J. Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene. Am. J. Hum. Genet. 84, 658–663 (2009).
Khattab, A. et al. Pitfalls in hormonal diagnosis of 17-β hydroxysteroid dehydrogenase III deficiency. J. Pediatr. Endocrinol. Metab. 28, 623–628 (2015).
Balducci, R. et al. Familial male pseudohermaphroditism with gynaecomastia due to 17β-hydroxysteroid dehydrogenase deficiency. A report of 3 cases. Clin. Endocrinol. 23, 439–444 (1985).
Boehmer, A. L. M. et al. 17β-Hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J. Clin. Endocrinol. Metab. 84, 4713–4721 (1999).
Chuang, J. et al. Complexities of gender assignment in 17β-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy? Int. J. Pediatr. Endocrinol. 2013, 15 (2013).
Elsas, L. J. et al. Gender verification of female athletes. Genet. Med. 2, 249–254 (2000).
Ha, N. Q. et al. Hurdling over sex? sport, science, and equity. Arch. Sex. Behav. 43, 1035–1042 (2014).
IAAF. Eligibility Regulations for the Female Classification (Athletes With Differences of Sex Development) 1–22 https://www.iaaf.org/download/download?filename=0c7ef23c-10e1-4025-bd0c-e9f3b8f9b158.pdf&urlslug=IAAF (1 November 2018).
Bartolone, L., Smedile, G., Arcoraci, V., Trimarchi, F. & Benvenga, S. Extremely high levels of estradiol and testosterone in a case of polycystic ovarian syndrome. Hormone and clinical similarities with the phenotype of the α estrogen receptor null mice. J. Endocrinol. Invest. 23, 467–472 (2000).
Legro, R. S. et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J. Clin. Endocrinol. Metab. 95, 5305–5313 (2010).
Vilain, E. & Martinez-Patiño, M. J. Science’s place in shaping gender-based policies in athletics. Lancet 393, 1504 (2019).
International Olympic Committee. 2011 Olympic Charter 1–95 https://stillmed.olympic.org/media/DocumentLibrary/OlympicOrg/General/EN-Olympic-Charter.pdf (2011).
Acknowledgements
The authors thank P. Speiser for helpful discussions while preparing the case report for Box 2 and M. Almalvez for assistance with references and figures. E.C.D. and E.V. are supported in part by grant R01HD093450 (Disorders/Differences of Sex Development Translational Research Network, DSD-TRN) from the Eunice Kennedy Shriver National Institute of Child Health and Development.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
E.V. has scientifically advised Bionano Genomics. E.C.D. declares no competing interests.
Additional information
Peer review information
Nature Reviews Genetics thanks C. Flueck, A. Sinclair and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
CAS Executive Summary: https://www.tas-cas.org/fileadmin/user_upload/CAS_Executive_Summary__5794_.pdf
ClinGen consortium: http://clinicalgenome.org/
Cystic Fibrosis Foundation: https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
Cystic Fibrosis Worldwide: https://www.cfww.org/
DSD-Life: https://www.dsd-life.eu/home/index.html
DSD/Primary adrenal deficiency WES-based test: https://www.radboudumc.nl/getmedia/ea3f05c7-2d81-4127-9d15-66aee97aff3e/DSDPRIMARYADRENALINSUFFICIENCY_DG300.aspx
DSD-TRN: https://dsdtrn.org
Franklin: https://franklin.genoox.com/clinical-db/home
Genoox sequence analysis platform: https://www.genoox.com/genoox-integrated-omsv-platform/
HIV.gov: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics
I-DSD: https://home.i-dsd.org
IRDiRC: https://irdirc.org/about-us/vision-goals/
Leiden Open Variation Database: www.lovd.nl
PanelApp: https://panelapp.genomicsengland.co.uk/panels/9/
Parkinson’s Foundation: https://www.parkinson.org/Understanding-Parkinsons/Statistics
SVI General Recommendations for Using ACMG/AMP Criteria: https://clinicalgenome.org/working-groups/sequence-variant-interpretation/
Supplementary information
Glossary
- Positive predictive value
-
(PPV). In a clinical test, the ratio of the number of individuals confirmed to have the condition being tested for to those who tested positive with the test, irrespective of disease status. The PPV predicts the likelihood of someone who tests positive for having the condition.
- Isodicentric Y
-
An abnormal Y chromosome resulting in two centromeres and two identical arms (Yp or Yq). Breakpoints vary, but individuals with two short (Yp) arms may have two copies of the testis-determining gene SRY (located in Yp11.2), whereas those with two long arms typically do not carry SRY.
- Cell-free fetal DNA
-
Fragments of DNA of fetal origin circulating in the maternal blood during pregnancy, which can be tested to screen for aneuploidies such as trisomy 21 or to ascertain the sex chromosome complement of the fetus.
- Copy number variants
-
(CNVs). Variants, typically larger than 50 bp, that result in increased or decreased ploidy, such as a deletion on an autosome resulting in a single copy of the region instead of two. CNVs are a type of structural variant.
- Chimerism
-
A condition whereby two different genomes are found in a single individual, usually as a result of fusion of two zygotes during a twin pregnancy. Differences of sex development can arise when the two genomes have a different sex chromosome complement (XX and XY).
- Mosaicism
-
A condition whereby two different genomes are found in a single individual, typically resulting from a post-fertilization mutation that is found only in the daughter cells of a subset of embryonic cells and thereby results in different phenotypic expression in different tissues. A frequent type of mosaicism associated with differences of sex development is Turner syndrome variants with 45,X/46,XY mosaic karyotypes.
- Structural variants
-
Variants including copy number variants, insertions, translocations or inversions. They can be balanced (when the rearrangement does not result in loss or gain of genomic material) or unbalanced.
- Epimutations
-
Heritable variants that modify gene expression through gain or loss of DNA methylation or other modification of chromatin without affecting the underlying DNA sequence.
- Episignatures
-
Unique patterns of epigenetic variation (typically DNA methylation) occurring at multiple nucleotide locations throughout the genome. Episignatures have shown potential diagnostic value in syndromic conditions where no underlying genetic aetiology is found.
Rights and permissions
About this article
Cite this article
Délot, E.C., Vilain, E. Towards improved genetic diagnosis of human differences of sex development. Nat Rev Genet 22, 588–602 (2021). https://doi.org/10.1038/s41576-021-00365-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41576-021-00365-5
This article is cited by
-
Reprograming skin fibroblasts into Sertoli cells: a patient-specific tool to understand effects of genetic variants on gonadal development
Biology of Sex Differences (2024)
-
A conserved NR5A1-responsive enhancer regulates SRY in testis-determination
Nature Communications (2024)
-
A novel c.64G > T (p.G22C) NR5A1 variant in a Chinese adolescent with 46,XY disorders of sex development: a case report
BMC Pediatrics (2023)
-
Variants in SART3 cause a spliceosomopathy characterised by failure of testis development and neuronal defects
Nature Communications (2023)
-
46,XY disorders of sex development: the use of NGS for prevalent variants
Human Genetics (2022)